Valdete Schaub
Tuebingen, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.
Journal: Blood
Published: September 15, 2025
MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.
Journal: Blood
Published: September 15, 2025
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial.
Journal: The Lancet. Oncology
Published: November 08, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: June 06, 2024
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 12, 2022
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma.
Journal: Infection
Published: November 23, 2021
Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety?
Journal: Health policy (Amsterdam, Netherlands)
Published: January 06, 2020
Showing 1-10 of 10
Last Updated: 09/26/2026